Breakthrough SARS-CoV-2 infections in an eastern state of India: A preliminary report | Research Square researchsquare.com/article/rs-649…
Out of 274 samples with breakthrough infection, 35 (12.8%) individuals received Covaxin and 239 (87.2%) individuals received Covishield. 
The median age for breakthrough infection among referred cases was 47.0 years (IQR: 28.0) with a signicantly older age group among Covishield recipients (Table 1).
Around 43% of the Covaxin recipients with breakthrough infection and reported to the facility were health care workers whereas it was around 10% in Covishield recipients and the difference was statistically signicant.
About 83.2% of individuals were found to be symptomatic in nature and which was almost similar in both the vaccine groups. Around 9.9% of the individuals were hospitalised with no signicant difference between Covaxin and Covishield recipient groups.
Only one individual (Covishield recipient) died post infection during the study period.
A total of 258 (94.2%) individuals were found to be positive for SARS-CoV-2 IgG antibodies against spike protein. There were signicant differences in seropositivity between Covaxin (77.1%) and Covishield (96.7%).
Recipients of Covishield showed higher median titre values than Covaxin among the reported cases which were statistically signicant. The median antibody titre values for Covaxin and Covishield were 213.5 AU/ml (IQR: 537.5) and 647.5 AU/ml (IQR: 1645.1) respectively.
Anti Body Titter against Spike Protein higher in Covishield than Covaxin.
A total of 274 cases were found to be infected with the SARS-CoV-2 virus ≥14 days after receiving a second COVID-19 vaccine (Covaxin or Covishield) dose and were dened as breakthrough infections.
Only 16.8% of individuals were asymptomatic with no difference in the ct values between the symptomatic and asymptomatic. Out of the 27 individuals with breakthrough infections and requiring hospitalizations, one died.
Limitations of Study:
The study has two limitations, firstly the number of documented COVID-19 vaccination breakthrough cases may be a signicantly underestimated of all SARS-CoV-2 infections among fully vaccinated persons and
The study has two limitations, firstly the number of documented COVID-19 vaccination breakthrough cases may be a signicantly underestimated of all SARS-CoV-2 infections among fully vaccinated persons and
secondly the data is based on passive and voluntary reporting of individual, and might not be complete representation of breakthrough cases as most asymptomatic individual or with mild illness post vaccination might have not got tested.
It is anticipated that even with administration of effective authorized vaccines, breakthrough cases are expected to happen, till the immunity reaches sucient levels among the population to further decrease transmission
Note on Study by ICMR in Odisha: (Summary)
While Covishield gives better anti body titter compared to Covaxin. But Covaxin had only 35 Breakthrough infections (12.8%) & Covishield had 239 Breakthrough infection (87.2%) of Total 274 Breakthrough infections post vaccination.
While Covishield gives better anti body titter compared to Covaxin. But Covaxin had only 35 Breakthrough infections (12.8%) & Covishield had 239 Breakthrough infection (87.2%) of Total 274 Breakthrough infections post vaccination.
📌Symptomic Cases in Breakthrough Infection:
Total: 228 of 274
📍Covaxin - 29
📍Covishield - 199
📌Hospitalisation
Total 27 of 274
📍Covaxin - 3
📍Covishield - 24
📌Deaths : 1 of 274 (Covishield)
Total: 228 of 274
📍Covaxin - 29
📍Covishield - 199
📌Hospitalisation
Total 27 of 274
📍Covaxin - 3
📍Covishield - 24
📌Deaths : 1 of 274 (Covishield)
Needless to say this Study doesnt guages the antibody response Covaxin induces against Nucleocapsid protein (N Protein) or Th1 Immune Cell response.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
